Strasbourg, France – December 8, 2025 – SC Medica today announced that its FFX® Facet FiXation System has received U.S. Food and Drug Administration (FDA) clearance for cervical use, marking a significant expansion of its clinical indications in the United States.
Following the recent FDA authorization of FFX® for standalone lumbar facet arthrodesis, this new clearance further confirms the system’s role as an emerging standard in posterior stabilization.
FFX®, now validated for use in the cervical spine, allows U.S. surgeons to perform cervical facet fusion procedures in selected patients.
“This new cervical indication represents another major step forward for facet-based stabilization,” said Camille Srour, Ph.D., Founder and CEO of SC Medica. “This reflects our long-standing commitment to achieving fusion with the Minimum Necessary Volume of Instrumentation – a concept we call MiNVI.”
With more than 11,000 implantations worldwide to date, FFX® stabilizes the posterior column through bilateral facet joint immobilization, simplifying the surgical workflow, reducing operative time, and lowering surgical morbidity compared with conventional fixation systems*.
About SC MEDICA
SC MEDICA, founded in 2015, is the leading facet arthrodesis company dedicated to providing innovative solutions for back-pain control and spinal fusion.
With a commitment to excellence and innovation, SC MEDICA aims to raise awareness of the role of facet joints in a large number of spinal conditions and to establish FFX® facet arthrodesis as a new gold standard in posterior stabilization.
* For more information about SC MEDICA’s FFX® device, visit www.sc-medica.com